MedTrace Logo

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-07-29

No results posted yet for this study

Summary

Toxicity of anti-IL-5

Conditions

  • Hypereosinophilic Syndromes
  • Eosinophilic Gastroenteritis
  • Churg-Strauss Syndrome
  • Eosinophilic Esophagitis

Interventions

DRUG

Mepolizumab

10mg/kg (max 750 ml) once a month for 3 months

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Marc E. Rothenberg, MD · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31
Primary Completion
2005-04-30
Completion
2005-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00266565 on ClinicalTrials.gov